HUMIRA® (adalimumab) for adults with Ulcerative Colitis (UC)
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis - Clinical Gastroenterology and Hepatology
Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study - Yamasaki - 2020 - The Journal of Dermatology - Wiley Online Library
Vedolizumab versus Adalimumab for Ulcerative Colitis (part 2) | gutsandgrowth
Ulcerative Colitis: Today, Tomorrow, and the Future - European Medical Journal
Efficacy | Ulcerative Colitis (UC) | HUMIRA® (adalimumab)
Ulcerative Colitis Remission & HUMIRA® Results (adalimumab)
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) - Gastroenterology
HUMIRA (adalimumab) for the Treatment of Ulcerative Colitis
The market for ulcerative colitis
Adalimumab may be efficacious, safe treatment for children with ulcerative colitis
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis - Gastroenterology
Real‐world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review - Khan - 2019 - Journal of Clinical Pharmacy
Adalimumab trials show low rate of IBD adverse events
HUMIRA (adalimumab) for the Treatment of Ulcerative Colitis
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study - The Lancet Gastroenterology & Hepatology
HUMIRA (adalimumab) Hidradenitis Suppurativa (HS) Safety Data
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years - ACR Meeting Abstracts
Ulcerative Colitis Clinical Trials - GEMINI I Study | Entyvio®
Ustekinumab for Ulcerative Colitis | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta property="og:image" content="https ...
HUMIRA (adalimumab) Citrate-Free | Official HCP Site
Why Have We Not Finally Figured Out Combination Therapy?
Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients | Scientific Reports
PDF) Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
